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PAST
Major liver resection for perihilar cholangiocarcinoma is
associated with 90-day mortality rates of up to 18% in
Western series.1 Posthepatectomy liver failure is the pri-
mary cause of the high perioperative mortality.2 However,
the golden standard preoperative procedure to reduce liver
failure and mortality—portal vein embolization—is spar-
sely used in Western centers for patients with perihilar
cholangiocarcinoma.3,4 This is in contrast to Eastern cen-
ters, where application of portal vein embolization is
liberal and mortality rates are lower.3
PRESENT
Our recent paper shows that application of preoperative
portal vein embolization before major liver resection for
perihilar cholangiocarcinoma is associated with marked
reductions in posthepatectomy liver failure and 90-day
mortality rates. Using data of 1667 patients from 20 cen-
ters, a propensity score matched comparison was
performed. In the matched cohort, liver failure and
mortality rates were 8% and 7%, respectively, with resec-
tion after portal vein embolization, compared with 36%
and 18%, respectively, after resection without portal vein
embolization (P\ 0.001 and P = 0.031).4 Although these
results might be expected, these analyses have not been
performed previously in a cohort with resections for only
perihilar cholangiocarcinoma. The disease most often
requires major liver resection as well as extrahepatic bile
duct resection, which alone is high-risk surgery. But these
patients often suffer from obstructive jaundice requiring
biliary drainage, which can induce cholangitis and further
increase the risk of adverse outcomes.
FUTURE
Perihilar cholangiocarcinoma is rare, and solid research on
the optimal treatment strategy is difficult. In our opinion, a
randomized trial on the effect of portal vein embolization is not
required and perhaps unethical in light of the currently avail-
able evidence. Future studies should focus on the optimal
indications for portal vein embolization. The goal is to provide
a curative resection to as many patients as possible, while
reducing the risks of adverse outcomes to a minimum. The
balance between these two is a challenge for future studies.
Perhaps alternative techniques such as quantitate liver function
assessment can help to select those patients who will especially
benefit from portal vein embolization.5
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